The use of the electromotive drug administration system in patients with overactive bladder: a review of the clinical effectiveness, safety, and cost-effectiveness
CADTH
Record ID 32015000151
English
Authors' recommendations:
Clinical evidence on the effectiveness of EMDA for treatment of overactive bladder is limited, and studies on cost-effectiveness could not be identified. EMDA therapy with botulinum toxin A for treatment of refractory neurogenic detrusor overactivity in children appears to be efficacious, while that with dexamethasone for treatment of idiopathic detrusor overactivity in adults does not.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/pdf/htis/dec-2014/RC0589%20EMDA%20for%20Overactive%20Bladder%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Urinary Bladder, Overactive
- Drug Delivery Systems
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.